NCT01175473 - Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes | Biotech Hunter

Enrollment

148

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Lixisenatide (AVE0010)

Self administered by subcutaneous injections once daily 30 minutes before breakfast.

DEVICE

Pen auto-injector

DRUG

Liraglutide

Self administered by subcutaneous injections once daily 30 minutes before breakfast.

DEVICE

Pre-filled pen injector

DRUG

Metformin

Metformin to be continued at stable dose (1.5 gram per day) up to Week 4.

Trial Locations (7)

Sanofi-Aventis Investigational Site Number 276006, Berlin

Sanofi-Aventis Investigational Site Number 276004, Kiel

Sanofi-Aventis Investigational Site Number 276005, Mönchengladbach

Sanofi-Aventis Investigational Site Number 276001, Neuss

Sanofi-Aventis Investigational Site Number 276002, Mainz

Sanofi-Aventis Investigational Site Number 276003, Mannheim

Sanofi-Aventis Investigational Site Number 276007, München